



ABN 53 075 582 740

ASX ANNOUNCEMENT
29 September 2015

Bionomics Appoints Dr. Alan W. Dunton to Board of Directors

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, has appointed Dr. Alan W. Dunton to the Company's Board of Directors as a non-executive director.

"Alan will be a very valuable addition to the Board given his enormous drug development and clinical research experience as well as his tenured career in the pharmaceutical industry," said Graeme Kaufman, Chairman of Bionomics. "His past career interests across many therapeutic areas have provided him deep sector knowledge in the target areas of Bionomics drug candidates and additionally, his insights as a physician and his experience on U.S. boards will help guide the Company towards the further development and potential commercialisation of its pipeline."

Dr. Dunton brings hands-on drug discovery, development and regulatory experience across all functional areas and has played a key role in the development of more than 20 products through to regulatory approval, including the successful OTC pain drug Aleve™. He served as President and Managing Director of the Janssen Research Foundation, a Johnson and Johnson company, the first American to hold that position. Subsequently Dr. Dunton served as President and Chief Executive Officer at Metaphore Pharmaceuticals and at Panacos Pharmaceuticals. Dr. Dunton founded Danerius, LLC, a specialist pharmaceutical and biotech consulting company. Dr. Dunton holds a M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine and was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.

He is currently serves as a Director of Palatin Technologies, Oragenics and Sancilio Pharma. He has previously served as a Director of several other companies including Targacept, Inc. and Emisphere Technologies.

Dr Dunton commented "Bionomics is an exciting company with a robust pipeline including BNC210 and BNC101. The company also has two impressive partnerships with Merck & Co. which validate its platform technologies. I am delighted to be joining the Board at this time as I believe Bionomics will be able to deliver meaningful and truly innovative treatments to patients and build substantial shareholder value".

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 is expected to enter clinical trials in the fourth quarter of 2015. Bionomics has strategic partnerships with Merck & Co. in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This presentation contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.